Clinical Trial Update: Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating selinexor in combination with VRd (bortezomib, lenalidomide, dexamethasone) for high-risk newly diagnosed multiple myeloma; recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)
• Velcade (bortezomib)
• XPOVIO (selinexor)

Snippet

Sponsor: Xia Zhongjun | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING